DOSE OF REALITY: NEW ICER REPORT FINDS BIG PHARMA’S LAUNCH PRICES REMAIN OUT OF CONTROL AND UNJUSTIFIED BY CLINICAL VALUE
Oct 21, 2026
Median Net Launch Prices Have Increased 35 Percent Since 2022… Read More
© 2026 CSRXP- All Rights Reserved
Dose of Reality
DOSE OF REALITY: JAMA STUDY FINDS DRUG PATENT PORTFOLIOS ON SMALL MOLECULE DRUGS HAVE MORE THAN TRIPLED, DELAYING GENERIC COMPETITION
Sep 30, 2026
New Analysis Shows Brand Name Drug Companies Increasingly Rely On Follow-On… Read More
DOSE OF REALITY: AARP ANALYSIS EXAMINES PATENT ABUSE ON BRAND NAME INHALER THAT KEPT PRICES HIGH FOR PATIENTS
Sep 30, 2026
Report Details How Tactics Like Patent Thicketing and Product Hopping Delayed… Read More
DOSE OF REALITY: BIOSIMILAR SLOWDOWN UNDERSCORES URGENCY FOR SOLUTIONS TO FOSTER GREATER COMPETITION, ENCOURAGE BIOSIMILAR DEVELOPMENT
Sep 16, 2026
Congress Should Pass Bipartisan, Market-Based Solutions to Reduce Unnecessary… Read More
DOSE OF REALITY: REPORT FINDS BIG PHARMA CONTINUES TO SET OUT-OF-CONTROL LAUNCH PRICES ON NEW MEDICINES COMING TO MARKET
Jul 2, 2026
Reuters Analysis Finds Average Launch Price For Drugs Approved By FDA in 2025… Read More
DOSE OF REALITY: AARP REPORT FINDS PRICES FOR TOP-SELLING BRAND NAME DRUGS RISE DRAMATICALLY IN THE U.S. WHILE FALLING IN OTHER COUNTRIES
Jun 2, 2026
Report Finds List Prices for Best-Selling Medicare Part D Prescription Drugs… Read More
Dose of Reality: I-MAK Report Outlines How Big Pharma Extends Monopolies to Keep Drug Prices High
Apr 24, 2026
Analysis Demonstrates Tremendous Cost of Anti-Competitive Tactics Like Patent… Read More
DOSE OF REALITY: GSK’S BRAND NAME INHALER BAIT-AND-SWITCH INCREASED COSTS AND WORSENED HEALTH OUTCOMES
Mar 18, 2026
New Report Details Impact of Big Pharma Giant’s Strategy to Maintain… Read More
DOSE OF REALITY: HEALTH AFFAIRS SCHOLAR ANALYSIS FINDS BIG PHARMA’S PATENT ABUSE GROWING IN SCALE, KEEPING PRESCRIPTION DRUG PRICES HIGH
Mar 3, 2026
New Report Demonstrates How Brand Name Drug Companies Wield Litigation Around… Read More
DOSE OF REALITY: LAWMAKERS HAVE OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR EGREGIOUS PRICING AND ANTI-COMPETITIVE PRACTICES DRIVING HEALTH CARE COSTS
Feb 10, 2026
Big Pharma Sets Out-of-Control Launch Prices, Hikes Prices Outpacing… Read More
DOSE OF REALITY: NEW CMS DATA UNDERSCORES HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES ARE DRIVING INCREASED HEALTH CARE COSTS
Jan 26, 2026
U.S. Prescription Drug Spending Climbs as Big Pharma Sets New Records for… Read More
DOSE OF REALITY: BIG PHARMA’S EGREGIOUS PRICING AND ANTI-COMPETITIVE PRACTICES ARE DRIVING RISING HEALTH CARE COSTS
Jan 22, 2026
Making Health Care Affordable for the American People Means Holding Big Pharma… Read More